Ilya Pharma have had a successful preIND meeting with the FDA related to the development of ILP100-Oral
Abstract: The Value of early Regulatory Interactions with Authorities for emilimogene sigulactibac (INN) - a new modality in gene therapy, to be presented by Margareth Jorvid Head of Regulatory Affairs
Conference topic is to - Reimagine the future of therapeutics
Bioprocessing and analytics industry business expert to spearhead major growth drive
Dr Andreas Fasth, Head of Clinical Developments and Medical Affairs at Ilya Pharma is on site and presenting "Accelerated wound healing by on-site production and delivery of CXCL12 by transformed lactic acid bacteria in 36 healthy volunteers with experimentally induced wounds".
Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents.